Bristol Myers Squibb (BMS), a major pharmaceutical company based in New Jersey, is generating excitement among investors with news about potential new medicines it\u2019s developing. These upcoming results could bring significant benefits to patients and help the company grow, especially as some of its current important medicines face upcoming patent expirations. Here\u2019s a breakdown of what\u2019s happening and what it means for you. <\/p>\n
During a recent earnings call on April 30th, BMS shared its financial results for the first three months of 2024. The company reported total revenues of $11.5 billion, which is a slight increase of 1% compared to the same time last year when accounting for changes in currency exchange rates. This result was slightly better than what financial analysts had predicted. <\/p>\n
While the overall growth was modest, BMS\u2019s newer medicines, which they call their ‘growth portfolio,’ saw a stronger increase of 9%, totaling $6.2 billion in revenue. One of their standout medicines in this category is Camzyos (mavacamten), used to treat a heart<\/a> condition called obstructive hypertrophic cardiomyopathy. This drug saw a huge jump in revenue of 97% compared to last year, bringing in $314 million in the first quarter alone. <\/p>\n BMS also confirmed its financial outlook for 2026, expecting total revenues to be between $46 billion and $47.5 billion. One of their biggest earners, Eliquis (apixaban), which is used to prevent blood clots, generated $4.1 billion in revenue during the first quarter\u2014an increase of 16% compared to the same time last year. However, Eliquis is facing a challenge: its patent is expected to expire in 2027, which could lead to cheaper generic versions becoming available and reduce BMS\u2019s earnings from this medicine<\/a>. <\/p>\n To prepare for this, BMS is focusing on developing new medicines to take its place. One of these is milvexian, a next-generation blood thinner that could be a strong competitor to Eliquis. Analysts and investors are closely watching the results of two important late-stage clinical trials for milvexian. These trials are testing the medicine\u2019s effectiveness in preventing strokes in patients with atrial fibrillation (an irregular heartbeat) and in preventing another stroke in people who have already had one. The results from these trials are expected later this year. <\/p>\n During the earnings call, BMS\u2019s executive Adam Lenkowsky described milvexian as having the potential to become a ‘blockbuster’ medicine\u2014meaning it could generate over $1 billion in annual sales\u2014if it proves to be more effective and safer than Eliquis, especially in terms of reducing bleeding risks. However, it\u2019s worth noting that in November 2023, BMS and its partner Johnson & Johnson stopped a late-stage trial of milvexian in patients with acute coronary syndrome (a type of heart attack) because the medicine was unlikely to meet its main goals. This raised some concerns among analysts about whether the ongoing stroke trials might also face challenges. <\/p>\n Another medicine generating interest is Cobenfy (xanomeline\/trospium chloride), which is used to treat schizophrenia. Approved in 2024, BMS sees it as a strong future growth opportunity despite Eliquis\u2019s patent challenges. In the first quarter of 2024, Cobenfy\u2019s global revenue increased by 107%, reaching $56 million. However, its adoption by doctors and patients has been slower than expected due to hesitation from physicians to prescribe it and challenges with insurance coverage for American patients. <\/p>\n